Morbidity and mortality on combination versus monotherapy: a posthoc analysis of the Systolic Hypertension in Europe trial
- PMID: 20051905
- DOI: 10.1097/HJH.0b013e32833627c9
Morbidity and mortality on combination versus monotherapy: a posthoc analysis of the Systolic Hypertension in Europe trial
Erratum in
- J Hypertens. 2010 Jun;28(6):1347-8
- J Hypertens. 2016 Mar;34(3):588
Abstract
Background: The current literature supports the immediate use of combinations of antihypertensive drugs in terms of ease of use and adherence, but the key issue whether combination therapy is more effective than monotherapy in the prevention of cardiovascular complications remains unproven.
Methods: We analysed the double-blind (median follow-up 2.0 years) and open follow-up (6.0 years) phases of the Systolic Hypertension in Europe trial. Patients were 60 years or more with an entry systolic/diastolic blood pressure (BP) of 160-219/less than 95 mmHg. Antihypertensive treatment started immediately after randomization in the active-treatment group, but only after completion of the double-blind trial in control patients. Treatment consisted of nitrendipine (10-40 mg/day) with the possible addition of enalapril (5-20 mg/day). We adjusted our analyses for sex, age, history of cardiovascular complications, baseline systolic BP and previous antihypertensive treatment.
Results: During the double-blind trial, adding enalapril to nitrendipine (n = 515), compared with the equivalent combination of placebos (n = 559), decreased systolic BP by a further 9.5 mmHg and reduced all cardiovascular events by 51% (P = 0.0035) and heart failure by 66% (P = 0.032), with similar trends for stroke (-51%; P = 0.066) and cardiac events (-44%; P = 0.075). Over the whole duration of follow-up, combination therapy (n = 871), compared with nitrendipine monotherapy (n = 1552), decreased systolic BP by 3.1 mmHg and reduced total mortality (-32%; P = 0.023), with similar trends for all cardiovascular events (-23%; P = 0.081) and stroke (-42%; P = 0.054).
Conclusion: Despite the limitations of a posthoc analysis, but congruent with the stronger BP reduction, our results suggest that combination therapy with nitrendipine plus enalapril might improve outcome over and beyond the benefits seen with nitrendipine monotherapy.
Similar articles
-
Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial.J Hypertens. 2004 Apr;22(4):847-57. doi: 10.1097/00004872-200404000-00029. J Hypertens. 2004. PMID: 15126928 Clinical Trial.
-
Dihydropyridine calcium-channel blockers for antihypertensive treatment in older patients--evidence from the Systolic Hypertension in Europe Trial.S Afr Med J. 2001 Dec;91(12):1060-8. S Afr Med J. 2001. PMID: 11845604 Clinical Trial.
-
Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive patients: results of the 3-month observational, post-marketing, multicentre, prospective CENIT study.Clin Drug Investig. 2009;29(7):459-469. doi: 10.2165/00044011-200929070-00004. Clin Drug Investig. 2009. PMID: 19499963
-
Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension.Drugs. 2004;64(10):1135-48. doi: 10.2165/00003495-200464100-00009. Drugs. 2004. PMID: 15139792 Review.
-
Blood pressure and stroke: an overview of published reviews.Stroke. 2004 Mar;35(3):776-85. doi: 10.1161/01.STR.0000116869.64771.5A. Epub 2004 Feb 19. Stroke. 2004. Corrected and republished in: Stroke. 2004 Apr;35(4):1024. PMID: 14976329 Corrected and republished. Review.
Cited by
-
Combination therapy in the treatment of hypertension.Drugs Context. 2018 Jun 6;7:212531. doi: 10.7573/dic.212531. eCollection 2018. Drugs Context. 2018. PMID: 29899755 Free PMC article. Review.
-
Hypertension in the elderly.Int J Hypertens. 2012;2012:859176. doi: 10.1155/2012/859176. Epub 2011 Aug 16. Int J Hypertens. 2012. PMID: 21876789 Free PMC article.
-
Comparative efficacy of different antihypertensive drug classes for stroke prevention: A network meta-analysis of randomized controlled trials.PLoS One. 2025 Feb 21;20(2):e0313309. doi: 10.1371/journal.pone.0313309. eCollection 2025. PLoS One. 2025. PMID: 39982885 Free PMC article.
-
Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost.J Clin Hypertens (Greenwich). 2020 Oct;22(10):1769-1779. doi: 10.1111/jch.14009. Epub 2020 Aug 20. J Clin Hypertens (Greenwich). 2020. PMID: 32815663 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical